SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    P. Goes, I. M. Melo, L. M. C. M. Silva, N. M. B. Benevides, N. M. N. Alencar, R. A. Ribeiro, V. Lima, Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats, Journal of Periodontal Research, 2014, 49, 1
  2. 2
    Paula Goes, Iracema M. Melo, Caio S. Dutra, Ana Patrícia S. Lima, Vilma Lima, Effect of alendronate on bone-specific alkaline phosphatase on periodontal bone loss in rats, Archives of Oral Biology, 2012, 57, 11, 1537

    CrossRef

  3. 3
    Jürg A Gasser, Peter Ingold, Andrea Venturiere, Victor Shen, Jonathan R Green, Long-Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat, Journal of Bone and Mineral Research, 2008, 23, 4
  4. 4
    Maria Luisa Brandi, Alberto Falchetti, What Is the Relationship Between Paget's Disease of Bone and Hyperparathyroidism?, Journal of Bone and Mineral Research, 2006, 21, S2
  5. 5
    Jean-Pierre Devogelaer, Modern Therapy for Paget??s Disease of Bone, Treatments in Endocrinology, 2002, 1, 4, 241

    CrossRef

  6. 6
    Martin Pecherstorfer, Ruth Jilch, Alain Sauty, Eva Horn, Andrea Vera Keck, Ilse Zimmer-Roth, Daniel Thiebaud, Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte Subpopulations, Journal of Bone and Mineral Research, 2000, 15, 1
  7. 7
    Herbert Fleisch, Bisphosphonates in Bone Disease, 2000,

    CrossRef

  8. 8
    Paul D Miller, Jacques P Brown, Ethel S Siris, Mohammad S Hoseyni, Douglas W Axelrod, Pirow J Bekker, A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone, The American Journal of Medicine, 1999, 106, 5, 513

    CrossRef

  9. 9
    H Buckler, W Fraser, D Hosking, W Ryan, M.J Maricic, F Singer, M Davie, I Fogelman, C.A Birbara, A.M Moses, K Lyles, P Selby, P Richardson, J Seaman, K Zelenakas, E Siris, Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study, Bone, 1999, 24, 5, 81S

    CrossRef

  10. 10
    Naoto O'uchi, Haruko Nishikawa, Taiji Yoshino, Hiroyuki Kanoh, Hiroyuki Motoie, Emi Nishimori, Toshio Shimaoka, Tetsushi Abe, Hisataka Shikama, Takashi Fujikura, Miyoko Matsue, Ichiro Matsue, Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs, Journal of Periodontal Research, 1998, 33, 3
  11. 11
    P Filipponi, S Cristallini, G Policani, C Casciari, F Gregorio, Paget’s disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate, Bone, 1998, 23, 6, 543

    CrossRef

  12. 12
    M. E. Martínez, M. T. Del Campo, M. A. Plaza, A. Torrijos, J. Gijón, Pamidronate and biochemical markers of bone turnover, Scandinavian Journal of Clinical & Laboratory Investigation, 1997, 57, 7, 581

    CrossRef

  13. 13
    Jorma E. Heikkinen, Katri S. Selander, Kalevi Laitinen, Ilkka Arnala, H. Kalervo Väänänen, Short-Term Intravenous Bisphosphonates in Prevention of Postmenopausal Bone Loss, Journal of Bone and Mineral Research, 1997, 12, 1